ALXO · Alx Oncology Holdings Inc

Track ALXO — free

$1.32 -0.07 (-5.04%)

Russell 2000 member Rebalance outlook locked

Market Cap

$192.21M

138.28M

Volume · Oct 1 329.37K Avg daily vol (3M) 1.02M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Q1 2026 earnings call transcript

call held May 8, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$80.89M

Trailing 12 months

Revenue growth YoY

-59.3%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-36.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$128.52M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+153.8%

Year over year · more shares

Price change (1Y)

-24.0%

Trailing year

Short interest

4.5%

Latest settlement · 7.8 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −25%

below

Price vs 50-day avg −26%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 20%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −30%

trailing

6-month return −18%

trailing

YTD return +23%

this year

Relative strength −30%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +36 funds added

Insider flow Distributing

Net -$5.4K over 90 days · 100% sells

Short interest Falling

4.54% of float · ▼ -11.2% MoM · 7.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

94 holders — mid 3-yr range

Squeeze score 52

elevated · 0–100

Fundamentals

Strong

EPS growth +26%

Y/Y

Free cash flow $-84.4M

Balance sheet $6.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 92%

annualized · 1-yr

Max drawdown −50%

past year

ATR 8.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−25% Bearish

Price vs 50-day avg

−26% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

20% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +36 funds added

Insider flow Distributing

Net -$5.4K over 90 days · 100% sells

Short interest Falling

4.54% of float · ▼ -11.2% MoM · 7.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

94 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 20% Range high $3

vs 200-day avg -25% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ALXO Alx Oncology Holdings Inc this stock	$192.21M	+23.0%	—	—	4.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 76.1%
Net QoQ: +10.9M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

6.3M

Days to cover: 7.8d
Change: -791.2K sh

View

Short Volume

Short vol %

59%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

14.9K

Value: $29.4K
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

31.4%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$5.4K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-101.7M
EPS diluted: $-1.90

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 19

View

Proposed Sales

Value

$135.2K

Shares: 20.0K
Filed: Jul 11, 2024

View

Earnings & Events

Earnings Calls

Last call

Sep 14, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ALXO	-5.4%	-29.8%	-18.2%	-28.0%	+23.0%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-4.8%	-29.9%	-30.4%	-27.4%	+11.2%

Key facts CIK 1810182 CUSIP 00166B105 13F (30d) 3 filings 3 filers Visit website Investor relations

ALXO · Alx Oncology Holdings Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance